Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus

Journal of Pathology

Volumn 228, Issue 1, 2012, Pages 99-112

  Moyes, Lisa H ^a   McEwan, Hamish ^a   Radulescu, Sorina ^b   Pawlikowski, Jeff ^c   Lamm, Catherine G ^c   Nixon, Colin ^c   Sansom, Owen J ^b   Going, James J ^a   Fullarton, Grant M ^a   Adams, Peter D ^c  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Barrett's oesophagus; dysplasia; metaplasia; oesophageal cancer; Wnt signalling

Indexed keywords

BETA CATENIN; BETA NAPHTHOFLAVONE; KI 67 ANTIGEN; MOLECULAR MARKER; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS DYSPLASIA; GENE TARGETING; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; METAPLASIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WNT SIGNALING PATHWAY;

ADENOCARCINOMA; ANIMALS; ANIMALS, OUTBRED STRAINS; BARRETT ESOPHAGUS; BETA CATENIN; CELL NUCLEUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; METAPLASIA; MICE; MICE, INBRED C57BL; PRECANCEROUS CONDITIONS; WNT SIGNALING PATHWAY;

EID: 84864776725     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4058     Document Type: Article

References (37)

1. Playford RJ,. New British Society of Gastroenterology (NSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2005; 55: 442-443.
2. Jankowski JA, Provenzale D, Moayyedi P,. Oesophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588-595.
3. Holmes RS, Vaughan TL,. Epidemiology and pathogenesis of esophageal cancer. Semin Radiother Oncol 2007; 17: 1-9.
4. Shaheen NJ, Richter JF,. Barrett's oesophagus. Lancet 2009; 373: 850-861.
5. Prasad GA, Bansal A, Sharma P, et al., Predictor of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010; 105: 1490-1502.
6. Abela JE, Going JJ, Mackenzie JF, et al., Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008; 103: 850-855.
7. Flejou J-F,. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005; 54: i6-i12.
8. Spechler SJ,. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 2011; 100: 927-935.
9. Reid BJ, Blount PL, Feng G, et al., Optimising endoscopic biopsy detection of early cancers in Barrett's high grade dysplasia. Am J Gastroenterol 2000; 95: 3089-3096.
10. Schnell TG, Sontag SJ, Chejfec G, et al., Long-term nonsurgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology 2001; 120: 1607-1619.
11. Vousden KH, Lane DP,. p53 in health and disease. Nature Rev Mol Cell Bio 2007; 8: 275-283.
12. Reid BJ, Prevo LJ, Galipeau PC, et al., Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96: 2839-2848.
13. Moskaluk CA, Heitmiller R, Zahurak M, et al., p53 and p21 WAF1/CIP1/SDI1 gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 1996; 27: 1211-1220.
14. Woodward TA, Klingler PJ, Genco PV, et al., Possible p53-independent expression of p21 WAF/CIP1 in Barrett's esophagus. Gastrointestinal Oncol 1998; A705.
15. Clevers H,. Wnt/beta-catenin signalling in development and disease. Cell 2006; 127: 469-480.
16. Clement G, Jablons DM, Benhattar J,. Targeting the Wnt signalling pathway to treat Barrett's esophagus. Exp Opin Ther Targets 2007; 11: 375-389.
17. Bian Y, Osterheld M, Bosman FT, et al., Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000; 114: 583-590.
18. -/- embryos. EMBO J 2004; 23: 1825-1833.
19. Kemp R, Ireland H, Clayton E, et al., Elimination of background recombination: somatic induction of Cre by combined transcriptional regulation and hormone binding affinity. Nucleic Acids Res 2004; 32: e92.
20. Harada N, Tamai Y, Ishikawa T, et al., Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 1999; 18: 5931-5942.
21. Kirkegaard T, Edwards J, Tovey S, et al., Observer variation in immunohistochemical analysis of protein expression; time for a change? Histopathology 2006; 48: 787-794.
22. Goh AM, Coffill CR, Lane DP,. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126.
23. Blache P, van de Wetering M, Duluc I, et al., SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004; 166: 37-47.
24. Wang X, Ouyang H, Yamamoto Y, et al., Residual embryonic cells as precursors of a Barrett's like metaplasia. Cell 2011; 145: 1023-1035.
25. Moll R, Franke WW, Schiller DL,. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
26. Clement G, Braunschweig R, Pasquier N, et al., Alterations of the Wnt signalling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006; 25: 3084-3092.
27. Choi YW, Heath EI, Heitmiller R, et al., Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod Pathol 2000; 13: 1055-1059.
28. Koppert LB, van der Velden AW, van der Wetering M, et al., Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear beta-catenin expression. Br J Cancer 2004; 90: 892-899.
29. Zou H, Molina JR, Harrington JJ, et al., Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005; 116: 584-591.
30. Clement G, Guilleret I, He B, et al., Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci 2008; 99: 46-53.
31. Bani-Hani K, Martin IG, Hardie LJ, et al., Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92: 1316-1321.
32. Sherr CJ,. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60: 3689-3695.
33. Pelengaris S, Khan M, Evan G,. c-MYC: more than just a matter of life and death. Nature Rev Cancer 2002; 2: 764-776.
34. Schmidt MK, Meurer L, Volkweis BS, et al., c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Dis Esophagus 2007; 20: 212-216.
35. Stairs DS, Nakagawa H, Klein-, Szanto A, et al., Cdx1 and c-Myc foster the intiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PLoS One 2008; 3: 3534.
36. Foster JM, Dominguez-, Steglich MA, Guioli S, et al., Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 1994; 372: 525-530.
37. Kong J, Crissey MA, Stairs DB, et al., Cox2 and β-catenin/T-cell factor signalling intestinalize human oesophageal keratinocytes when cultured under organotypic conditions. Neoplasia 2011; 13: 792-805.